RILUTEK IN SLOWING PROGRESSION OF FTD

RILUTEK 减缓 FTD 的进展

• 批准号: 6219948
• 负责人: Bruce Lee Miller
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219948
• 关键词: clinical research; clinical trials; dementia; drug screening /evaluation; electromyography; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; magnetic resonance imaging; mental disorder chemotherapy; neuropharmacologic agent; psychological tests; single photon emission computed tomography

To investigate the medicine Rilutek as a possible treatment for Frontotemporal Dementia. Rilutek is currently approved by the FDA for treatment of amyotrophic Lateral Sclerosis. FTD is a cortical degenerative disorder that often occurs in association with ALS. The relationship between ALS and FTD is unexplained but needs further study. Patients with FTD between the ages of 40 and 90 years of age, Patients will have their memory and thinking tested, will have an MRI, SPECT and EMG performed and will have blood drawn at every visit to monitor any adverse effects.

目的：探讨利鲁替克治疗额颞叶痴呆的可能性。Rilutek目前被FDA批准用于治疗肌萎缩侧索硬化症。FTD是一种皮质退行性疾病，常与ALS相关。ALS和FTD之间的关系尚不清楚，但需要进一步研究。对于年龄在40岁到90岁之间的FTD患者，患者将接受记忆力和思维测试，并将进行MRI、SPECT和EMG检查，并在每次就诊时抽血监测任何不良反应。